| Titre : | Effect of HAART on health status and hospital costs of severe HIV-infected patients: a modeling approach |
| Type de document : | Article scientifique |
| Auteur(s) : | Le Pen C ; Rozenbaum W ; Downs A ; Maurel F ; Lilliu H ; Brun C |
| Appartenance auteur(s) InVS | DIT |
| Année de publication : | 2001 |
| Article en page(s) : | 136-45 |
| Langues : | Anglais (eng) |
in HIV clinical trials [HIV Clin Trials] > Vol. 2, N° 2 (04/2001) . - 136-45| Mots-clés : | Traitement antirétroviral ; Evaluation économique ; Hôpital ; Modèle ; Coût hospitalisation ; Enquête ; France
|
| Mots-clés : | SEROPOSITIVITE IMPACT |
| Résumé : | PURPOSE: The purpose of this study was to assess the impact of highly active antiretroviral therapy (HAART) on health status and hospital costs in severe HIV-infected patients who were followed in a French hospital. METHOD: The first 500 patients who received HAART, with CD4 + cell count below 250/mm3, were considered. Evolution of the distribution of patients among different health states, including death, was modeled through a continuous time Markov model. Hospital financial charges and antiretroviral treatment costs were computed. Health states defined by both CD4 counts and viral load were used to show clinical changes in the patient population over a 14-month period after HAART initiation. The economic impact of HAART initiation was assessed using a simplified model based on CD4 counts only over two 14-month periods, before and after initiation. RESULTS: Between day 0 and month 14, the proportion of patients in the least severe state (CD4 + >100/mm3 and viral load |
| PMID Pubmed : | Pubmed : 11590522  |
| Corpus : | Production scientifique InVS |
| Permalink : | http://opac.invs.sante.fr/index.php?lvl=notice_display&id=4165 |
> Mots outils [NI] > Méthodologie > Evaluation > Evaluation économique 
Analyse coût avantage
Ajouter le résultat dans votre panier Affiner la rechercheEffect of HAART on health status and hospital costs of severe HIV-infected patients: a modeling approach / Le Pen C in HIV clinical trials [HIV Clin Trials], Vol. 2, N° 2 (04/2001)
